Skip to content
drillr.ai

DRTS

Alpha Tau Medical Ltd.

NASDAQ · ILHealthcareBiotechnology
$13.47-0.59%

Price as of Jul 20, 2026

DRTS news

Alpha Tau Medical Ltd. news

A server-rendered, paginated timeline of the latest available company news.

  1. Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

    - Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile - - Completion of patient enrollment in the U.S. pivotal ReSTART trial in recurrent cutaneous squamous cell carcinoma, the Company’s first U.S. pivotal study - - Pooled data from two pancreatic cancer trials presented at Digestive Disease Week (DDW) 2026 demonstrated 100% local disease control and favorable safety, th

    Globe Newswire ·

  2. Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

    JERUSALEM, May 08, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd (https://www.globenewswire.com/Tracker?data=drw0Himqme34d8cLqtNmzm-LZUfWwES1zwfTChq8S7H7tEavj5EiGRs47qlLe6wx-kycpm4sqzqUDN5rx9XNkqRgcj8qUqdxPWHoNMHxunE=). (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT(®) today announced that it will host a conference call and webcast on Monday, May 11, 2026 at 8:30am ET to discuss interim clinical data from the firs

    Globe Newswire ·

  3. Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab

    - Abstract from trial evaluating Alpha DaRT(®) in combination with pembrolizumab in elderly patients with locally advanced and metastatic head and neck squamous cell carcinoma selected for podium presentation - - The AHNS International Conference on Head and Neck Cancer is widely recognized as one of the premier global forums dedicated to advancing head and neck oncology - - Clinical trial builds on Alpha DaRT monotherapy data generated across clinical studies in the United States, Europe, Isr

    Globe Newswire ·

  4. Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026

    - 100% local disease control rate achieved in evaluable patients in pooled analysis of two first-in-human trials of Alpha DaRT(®) in pancreatic adenocarcinoma - - Favorable safety profile observed, with only 8 device-associated adverse events in 7 of 26 subjects (27%), nearly all resolving within two weeks in some of the most challenging, heavily pre-treated patients in oncology - - Highly heterogeneous patient population for whom available options are extremely limited included patients ineli

    Globe Newswire ·

  5. Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies

    - Abstract accepted at the American Society of Clinical Oncology (ASCO) Annual Meeting - the world’s largest and most prestigious medical oncology conference - - Pooled analysis combines safety and efficacy data from 58 patients across three prospective clinical studies conducted at centers in Canada and Israel - - Acceptance of abstract comes in the same year as presentations at the ASCO Gastrointestinal Cancers Symposium and at Digestive Disease Week (DDW), reflecting growing interest within

    Globe Newswire ·

  6. Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial

    * ACAPELLA is the European multicenter clinical trial evaluating Alpha DaRT alpha-emitter radiotherapeutics combined with capecitabine for inoperable LAPC patients who have completed first-line mFOLFIRINOX, a population for whom no standard consolidation therapy exists and whose prognosis remains poor despite completing the best available systemic treatment * Approximately 30% of the estimated 140,000 Europeans diagnosed with pancreatic cancer each year present with locally advanced, inoperable,

    Globe Newswire ·

  7. Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026

    JERUSALEM, March 31, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd (https://www.globenewswire.com/Tracker?data=uo1-nlaQihuNkOmg2VvEOCEywacVu69z3JDeWIXE0XDlxihzHI2NLimNNsFV8N7tdsGjvfj1htYeR2706Rxxu8vLEylVR8nP2_tzCfquZrg=). (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT(®) today announced that an abstract presenting results of two clinical trials in Jerusalem in patients with pancreatic cancer has been accepted for an oral presentati

    Globe Newswire ·

  8. Alpha Tau to Present at Sidoti March Virtual Small Cap Conference

    JERUSALEM, March 16, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd (https://www.globenewswire.com/Tracker?data=DTUDVh-jOFWxfcta0pHhDjqENYPuTWiTTfPhIBdlEdUqMmc6ShDPL71NsIySXKVBlztDshNj_B2Gz3F3Rh2KJAUVAqUyJcpEfrGzES5YHtg=). (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT(®) today announced that CFO Raphi Levy will present at the Sidoti Virtual Small Cap Conference taking place on March 18-19, 2026. Event: Sidoti Virtual Small Cap Conf

    Globe Newswire ·

  9. Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update

    - Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and the first brain cancer treatment - - Multiple meaningful milestones targeted in the coming months, including completion of patient recruitment in the U.S. pivotal ReSTART skin cancer trial, in the U.S. pilot IMPACT pancreatic cancer trial, and in the U.S. recurrent glioblastoma multiforme feasibili

    Globe Newswire ·